

# Neonatal Congenital Infection Screening

Version	Status	Authorisation	Consensus Date
1.1	<ul style="list-style-type: none"><li>• Minor formatting changes</li><li>• Additional minor information added in multiple sections</li><li>• Preferred serology tube further outlined</li></ul>	Head of Department – Microbiology	17 <sup>th</sup> September 2025
1.0	Initial document	Head of Department – Microbiology	4 <sup>th</sup> September 2021

## Introduction

The TORCH acronym is a prompt to remember key infections in a pregnant individual and neonate. Untargeted TORCH serology testing has been repeatedly demonstrated to have very low utility. Consequently, the request “TORCH screen” is no longer provided at PathWest laboratories.

It is recommended that the clinical pattern of disease be used as a guide to specific testing (see table 1 and 2). This document is intended to guide appropriate microbiological diagnostic sampling. Due to their breadth, additional investigations such as liver function tests, coagulation profiles and radiological imaging that may aid in establishing a diagnosis are not included.

Of note, maternal booking bloods are stored in the laboratory for at least one-year post receipt. Dependent on the provider of antenatal care, these samples may be stored at PathWest or an external pathology provider. These samples can be used as an additional time point to demonstrate seroconversion, where required.

Polymerase chain reaction (PCR) is a nucleic acid amplification test that detects DNA or RNA of the targeted pathogen.

A Clinical Microbiologist can guide test result interpretation, where required.

## Guide

**Table 1:** Neonatal Infection Differential Guided by Presentation

**Table 2:** Test Selection by Potential Aetiology

**Table 3:** Test Sample Type and Volume

**Table 1: Neonatal Infection Differential Guided by Presentation**

Signs & symptoms	CMV	Enterovirus	HSV	Parvovirus B19	Rubella <sup>&amp;</sup>	<i>Toxoplasma</i>	<i>T. pallidum</i> (Syphilis)	Varicella (VZV) <sup>^</sup>	Zika virus <sup>#</sup>
<b>Cranial/ eye abnormalities/ hearing</b>									
Microcephaly	+				+	+		+	+
Hydrocephalus	+					+		+	+
Intracranial calcifications	+				+	+		+	+
Cataracts or microphthalmia	+				+	+		+	+
Chorioretinitis	+				+	+	+	+	+
Failed newborn hearing screen	+				+				+
<b>Liver</b>									
Hepatomegaly/ Jaundice/ hepatitis	+	+	+	+	+	+	+		
<b>Haematological abnormality</b>									
Anaemia	+	+	+	+			+		
Thrombocytopaenia	+	+	+	+			+		

**Table 1 (continued)**

Signs & symptoms	CMV	Enterovirus	HSV	Parvovirus B19	Rubella <sup>&amp;</sup>	<i>Toxoplasma</i>	<i>T. pallidum</i> (Syphilis)	Varicella (VZV) <sup>^</sup>	Zika virus <sup>#</sup>
<b>Skin/ limbs</b>									
Vesicles or blisters		+	+				+	+	
Rash (non-vesicular)	+	+	+		+		+	+ ^	
Limb hypoplasia or shortening								+	
Arthrogryposis									+
<b>Neonate size</b>									
Hydrops fetalis				+			+		
Intrauterine growth restriction	+				+		+	+	+
<b>Cardiac</b>									
Myocarditis	+	+	+	+	+				
Structural abnormalities					+ <sup>%</sup>				+
<b>Other</b>									
Unexplained sepsis	+	+	+				+		

**Table 1:** Neonatal signs and symptoms. <sup>&</sup> Congenital rubella is highly unlikely in the setting of demonstrated maternal immunity; check maternal results prior to consideration of testing of the neonate. <sup>^</sup> May be relevant in the setting of maternal infection consistent with primary varicella infection (chickenpox) during the first two trimesters of pregnancy. Skin thickening and scarring, particularly in a dermatomal distribution is characteristic. May be associated with limb malformation or atrophy. <sup>#</sup> Compatible exposure history required. This includes maternal travel to an area with known Zika activity or sex without a condom with someone who lives or travelled in an area with Zika activity. <sup>%</sup> Although a variety of abnormalities may be produced, the most frequently include pulmonary artery stenosis and patent ductus arteriosus.

**Table 2: Test Selection by Potential Aetiology**

Aetiology	Neonatal test selection
<b>Cytomegalovirus</b>	<ul style="list-style-type: none"> <li>• <b>1 X urine CMV PCR:</b> If positive, see Child and Adolescent Health Service congenital CMV pathway for interpretation and management</li> </ul>
<b>Enterovirus</b>	<ul style="list-style-type: none"> <li>• Throat and rectal swab for enterovirus PCR</li> <li>• CSF testing and blood PCR can be considered</li> </ul>
<b>Herpes simplex virus (HSV-1 and HSV-2)</b>	<p>Testing guided by risk assessment and symptoms. See <a href="#">ASID perinatal guidelines</a> for risk assessment and management. Note, HSV serology is not useful in the diagnosis of neonatal infection.</p> <p><b>High risk or symptomatic infant:</b></p> <ul style="list-style-type: none"> <li>• <b>HSV PCR:</b> Surface swabs of eye, throat, umbilicus, rectum and any skin lesions, if present <b>AND</b></li> <li>• <b>HSV PCR:</b> EDTA whole blood <b>AND</b></li> <li>• <b>HSV PCR:</b> Cerebrospinal fluid (if no contraindications for lumbar puncture).</li> </ul>
<b>Human immunodeficiency virus</b>	<p>Neonates born to mothers with known HIV infection will have an action plan. Discuss testing with Perth Children's Hospital Infectious Diseases service. In other cases, maternal testing is the preferred method of screening. If maternal screening is not possible, serology testing on an infant sample can be performed.</p>

<b>Parvovirus B19</b>	<p>Neonatal testing rarely indicated. Consider:</p> <ul style="list-style-type: none"> <li>• <b>Parvovirus serology:</b> for initial testing, maternal screening preferred.</li> <li>• <b>Parvovirus PCR:</b> On EDTA whole blood (if maternal screening not available or concern of post-natal acquisition)</li> </ul>
<b>Rubella</b>	<p>Highly unlikely in the setting of demonstrated maternal immunity to rubella. Check maternal results prior to consideration of testing of the neonate.</p> <ul style="list-style-type: none"> <li>• <b>Rubella PCR:</b> Urine</li> </ul>
<b><i>Toxoplasma gondii</i></b>	<p>First, confirm maternal history of infection (IgG positivity)</p> <p>If maternal IgG positive and neonatal infection suspected:</p> <ul style="list-style-type: none"> <li>• <b><i>Toxoplasma</i> serology (IgG and IgM):</b> Measure IgG in parallel with maternal sample (collect maternal sample at time of testing neonate)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• <b><i>Toxoplasma</i> PCR:</b> Placental tissue, EDTA whole blood +/- cerebrospinal fluid</li> </ul>
<b><i>Treponema pallidum</i> (syphilis)</b>	<p>Confirm maternal history of infection- syphilis serology test. If positive, approach based on risk assessment (see CAHS neonatal syphilis guideline).</p> <p>To detect congenital syphilis in high-risk infants, perform:</p> <ul style="list-style-type: none"> <li>• <b>Maternal Syphilis serology</b></li> <li>• <b>Neonatal serology (IgM and RPR measured <u>in parallel with maternal sample</u>):</b> Do not use cord blood.</li> <li>• <b>Syphilis PCR:</b> <ul style="list-style-type: none"> <li>• Placental tissue</li> <li>○ Nasal swabs</li> <li>○ Skin lesions (if present)</li> </ul> </li> </ul> <p><b>Cerebrospinal fluid:</b> sampling can be considered in high-risk neonate and should be discussed with Clinical Microbiologist and/ or Perth Children's Hospital Paediatric Infectious Diseases team prior to collection to guide appropriateness and test selection.</p>

<b>Varicella Zoster Virus (VZV)</b>	<p><b>Congenital varicella syndrome:</b> Diagnosis in the neonate is largely dependent on the diagnosis of maternal infection during pregnancy and consistent clinical findings in the neonate.</p> <p><b>Perinatal varicella infection</b> (where primary maternal VZV infection occurs less than 7 days prior to delivery):</p> <ul style="list-style-type: none"> <li>• <b>Lesion/vesicle:</b> Varicella PCR</li> </ul>
<b>Zika virus</b>	<p>Confirm maternal exposure history and serology results before testing neonate. If interpreted as consistent with possible recent infection</p> <ul style="list-style-type: none"> <li>• <b>Zika PCR:</b> perform on <ul style="list-style-type: none"> <li>○ Placenta tissue</li> <li>○ EDTA whole Blood</li> <li>○ Urine</li> <li>○ Cerebrospinal fluid: If very high clinical suspicion and other PCRs/ serology not diagnostic, CSF PCR recommended</li> </ul> </li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• <b>Serology: Zika</b> IgM and IgG</li> </ul>

**Table 2:** Test selection by potential aetiology

**Table 3: Test Sample Type and Volume**

Aetiology	Serology* “Gold top” tube preferred		PCR #		
	IgM	IgG	Blood (EDTA tube&)	CSF and Other fluid	Swab type% and site
<b>Cytomegalovirus</b>	X	X	500 µL	200 µL	X
<b>Enterovirus</b>	X	X	500 µL	200 µL	Dry swab: throat and rectal swab
<b>Herpes simplex virus (HSV-1 and HSV-2)</b>	X	X	500 µL	200 µL	Dry swab: swabs of eye, throat, umbilicus and rectum for HSV PCR, collected 24hrs post delivery
<b>Human immunodeficiency virus</b>	X		See neonatal plan	X	X
<b>Parvovirus B19</b>	325 µL	325 µL	500 µL	200 µL	X
<b>Rubella</b>	X	X	X	200 µL	X
<b><i>Toxoplasma gondii</i></b>	300 µL	300 µL	500 µL	200 µL	X
<b><i>Treponema pallidum</i> (syphilis)</b>	500 µL		X	X <sup>s</sup>	Dry swab: nasal +/- lesion
<b>Varicella (VZV)</b>	X	X	500 µL	X	Dry swab: lesion
<b>Zika Virus</b>	50 µL	50 µL	500 µL	200 µL	X

**Table 3:** Test sample type and blood volume. \* A “gold top” serum separator tube (SST) is preferred for both neonates and adults. Alternative options for neonates, in order of preference, include the SST microtainer and the red-top microtainer. For serology tests (IgG and IgM), the minimum stated volumes are per specified test and should be added together to calculate the required volume for collection. As an example, if both parvovirus IgG and IgM are required, the minimum serum volume is 650 µL blood. Sample volumes in this guide are expressed in whole blood volume, based on a neonate with a haematocrit of 55%. # For PCR, a single sample can be used to process multiple tests. &A dedicated EDTA tube is required i.e., this tube can only be used for PCR and not for any other tests. % Any dry swab type is acceptable. Swabs in charcoal or amies are not acceptable. <sup>s</sup> Cerebrospinal fluid sampling can be considered in high-risk neonate and should be discussed with clinical microbiologist and/ or Perth Children's hospital Infectious Disease team prior to collection to guide appropriateness and test selection. PCR, polymerase chain reaction; CSF, cerebrospinal fluid.



## Bibliography

### CMV

- The “Silent” Global Burden of Congenital Cytomegalovirus. CMR 2013; Jan 26(1)86 –102 [doi.org/10.1128/CMR.00062-12](https://doi.org/10.1128/CMR.00062-12)

### Enterovirus

- Neonatal enterovirus infections: emphasis on risk factors of severe and fatal infections. PIDJ: Oct 2003 - 22 (10)889-895 doi: [10.1097/01.inf.0000091294.63706.f3](https://doi.org/10.1097/01.inf.0000091294.63706.f3)

### HSV

- See KEMH [maternal](#) and [neonatal](#) guidelines
- Mother-to-Child Transmission of Herpes Simplex Virus. J Pediatric Infect Dis Soc. 2014 Sep; 3(Suppl 1): S19–S23. doi: [10.1093/jpids/piu050](https://doi.org/10.1093/jpids/piu050)

### Parvovirus

- Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010 Oct-Dec; 4(4): 63–66.
- Parvovirus B19 Infection in Pregnancy. JOGC 2014, 36(12)1107-1116 [doi.org/10.1016/S17012163\(15\)30390-X](https://doi.org/10.1016/S17012163(15)30390-X)
- Parvovirus B19 infection in human pregnancy. BJOG 2011(118)175–186. Doi: [10.1111/j.14710528.2010.02749.x](https://doi.org/10.1111/j.14710528.2010.02749.x)

### Rubella

- Chapter 15: Congenital Rubella Syndrome. Manual for the Surveillance of Vaccine Preventable Diseases. Date accessed 19<sup>th</sup> April 2021 [Link](#)
- Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2000–2018. MMWR Morb Mortal Wkly Rep. 2019 Oct 4; 68(39): 855–859. doi: [10.15585/mmwr.mm6839a5](https://doi.org/10.15585/mmwr.mm6839a5)

### Toxoplasma

- Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clinical Microbiology Reviews Apr 2012, 25 (2) 264-296; DOI: [10.1128/CMR.05013-11](https://doi.org/10.1128/CMR.05013-11)
- Congenital Toxoplasmosis. J Pediatric Infect Dis Soc. 2014 Sep; 3(Suppl 1): S30–S35. doi: [10.1093/jpids/piu077](https://doi.org/10.1093/jpids/piu077)

## Syphilis testing

- See KEMH [maternal](#) and CAHS [neonatal](#) guidelines

## Varicella

- Congenital varicella syndrome: A systematic review. J Obstet Gynaecol. 2016 Jul;36(5):563-6. doi: [10.3109/01443615.2015.1127905](#)
- Management of varicella in neonates and infants. BMJ Paediatrics Open. 2019;3:e000433. doi: [10.1136/bmjpo-2019-000433](#)

## Zika virus

- Zika virus - information for clinicians and public health practitioners. The Department of Health. Australian Government. Date accessed 19<sup>th</sup> April 2021 [Link](#)
- Response to Zika; Implementing CDC guidance. Centre for Disease Control and Prevention. Date accessed 19<sup>th</sup> April 2021 [Link](#)

Feedback:	<a href="mailto:David.foley@health.wa.gov.au">David.foley@health.wa.gov.au</a>		
Document Owner:	Head of Department – Microbiology		
Reviewer / Team:	The PK Microbiology team		
Date First Issued:	February 2022	Last Reviewed:	June 2025
Amendment Dates:	-	Next Review Date:	June 2028
Approved by:	Clinical Microbiology, PathWest QEII	Date:	February 2025
Endorsed by:	Paediatric Infectious Diseases, Perth Children's Hospital; King Edward Memorial Hospital Neonatology and Maternal-Fetal Medicine	Date:	May 2025
<b>Printed or personally saved electronic copies of this document are considered uncontrolled</b>			